Drug Trial Radar · NCT06320067
A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,360
Planned (sponsor's estimate)
Start
Jun 11, 2024
Primary completion
Apr 2031
Study completion Mar 2032
Sponsor
- Lead sponsor
- University College, LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cancer Research UK; Novartis
- First posted
- Mar 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
STAMPEDE2 is a clinical trial comparing two new treatments with standard of care in people with prostate cancer that has spread to other parts of the body and is responsive to hormone therapy. People from all backgrounds and ethnicities are encouraged to take part and multiple hospitals across the UK are involved. University College London is running the trial. Each comparison within the trial has its own control arm where people get the best standard of care (Arm A) versus a research arm where a new treatment is added to standard of care. Participants are allocated to an arm by a computerised system with a 50% chance of getting the research treatment. Comparison S: Arm A versus Arm S (Stereotactic Ablative Body Radiotherapy (SABR)) - Tests whether giving targeted doses of radiotherapy (SABR) to parts of the body where the cancer has spread slows the spread of the cancer and improves survival. 2476 people will be in this comparison. Comparison P: Arm A versus Arm P (PSMA-Lutetium (177Lu-PSMA-617)) - Tests whether giving a radioactive material (177Lu-PSMA-617) that targets prostate cancer cells slows the spread of the cancer and improves survival. 1756 people will be in this comparison. All participants will be followed up with scans and tests to monitor their cancer. Doctors will check for any side effects from the treatments. Treatments will be stopped if side effects are serious, or people no longer wish to take the treatments.
Conditions
- Prostate Cancer Metastatic
Interventions
Stereotactic Ablative Body Radiotherapy (SABR)Radiation
SABR is a way of giving focused high-dose radiotherapy. SABR given with a dose fractionation schedule of 27-30Gy in 3-5 fractions over 1-2 weeks to up to 5 metastatic lesions in the bone and/or non-regional (extra-pelvic) lymph nodes.
177Lu-PSMA-617Other
177Lu-PSMA-617 is a nuclear medicine therapy. Patients will receive 177Lu-PSMA-617 to a dose of 7.4GBq. Each cycle will consist of 2 doses, 1 week apart (on day 1 and day 8) and will last 6 weeks. Treatment will be given for up to 3 cycles (6 doses).
Androgen Deprivation Therapy (ADT)Drug
Long-term, continuous treatment with ADT (bilateral orchidectomy, LHRH agonists or LHRH antagonists) if not previously surgically castrated. The choice of ADT is at the discretion of the investigator. This will be given as standard of care as per local guidelines.
Androgen Receptor Signalling Inhibitor (ARPI)Drug
Second generation ARPI (Abiraterone Acetate and Prednisolone, Enzalutamide, Apalutamide or Darolutamide). This will be given as standard of care as per local guidelines. Abiraterone acetate will be administered as a single 1000mg once daily dose (4 tablets to be taken together once a day) with prednisolone 5mg once daily to prevent secondary mineralocorticoid excess. Enzalutamide will be administered as a 160mg oral dose (four capsules taken together at the same time every day) with or without food. Enzalutamide is administered daily in 28-day cycles. Apalutamide will be administered as 240mg oral dose (four tablets taken together at the same time every day) with or without food. Apalutamide is administered daily in 28-day cycles. Patients require thyroid function monitoring. Darolutamide will be administered as 600mg oral dose (two 300mg tablets taken together) with or without food. Darolutamide is administered twice daily in 28-day cycles.
Radiotherapy to Prostate ± Pelvic NodesRadiation
Either 36.25Gy given in 5 fractions over 1-2 weeks to prostate or 60Gy in 20 fractions over 4 weeks to prostate (± 44-47Gy in 20 fractions to pelvic lymph nodes ± 51Gy in 20 fractions boost to involved nodes).
DocetaxelDrug
Maximum of 6 cycles every 3 weeks may be given at a dose of 75mg/m2 by IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Final analysis for each comparison triggered when adequate number of death events have occurred in control arm of each comparison. Anticipate final reporting for OS in Comparison S: ~84 months (7 years) from FPFV, P: ~64 months (5.3 years) from FPFV.
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Mount Vernon Hospital
Barnsley, United Kingdom · Recruiting
Addenbrookes
Cambridge, United Kingdom · Recruiting
Royal Devon University Hospital Trust
Exeter, United Kingdom · Recruiting
Royal Devon & Exeter Hospital
Exeter, United Kingdom · Recruiting
The Princess Alexandra Hospital
Harlow, United Kingdom · Recruiting
University College London Hospitals NHS Foundation Trust
London, United Kingdom · Recruiting
The Royal Marsden Hospital
London, United Kingdom · Recruiting
Barts Health NHS Trust
London, United Kingdom · Recruiting
North Middlesex Hospital
London, United Kingdom · Recruiting
Royal Free Hospital
London, United Kingdom · Recruiting
The James Cook University Hospital
Middlesbrough, United Kingdom · Recruiting
Churchill Hospital
Oxford, United Kingdom · Recruiting
Derriford Hospital
Plymouth, United Kingdom · Recruiting
Queen Alexandra Hospital
Portsmouth, United Kingdom · Recruiting
Barking, Havering and Redbridge University Hospitals NHS Trust
Romford, United Kingdom · Recruiting
North Tees Health NHS Trust
Stockton-on-Tees, United Kingdom · Recruiting
The Royal Marsden Hospital
Sutton, United Kingdom · Recruiting
Kings Mill Hospital
Sutton in Ashfield, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.